

AD _____

Award Number: W81XWH-08-1-0471

TITLE: Quantification of Protein Signatures in Archived Human Prostate Tissues Using Shotgun Proteomic Methods

PRINCIPAL INVESTIGATOR: Michael Wright

CONTRACTING ORGANIZATION: University of Iowa
Iowa City, IA 52242

REPORT DATE: June 2011

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE June 2011		2. REPORT TYPE Annual		3. DATES COVERED 1 May 2010 – 31 May 2011	
4. TITLE AND SUBTITLE Quantification of Protein Signatures in Archived Human Prostate Tissues Using Shotgun Proteomic Methods				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-08-1-0471	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Michael Wright E-Mail: michael-e-wright@uiowa.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Iowa Iowa City, IA 52242				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Biomarkers that robustly predict the metastatic potential of localized CaP are sorely needed to effectively treat localized CaP patients that pose the greatest risk of developing significant CaP. Biomarkers specific to significant CaP are also necessary if more effective drugs are going to be developed that can target and cure patients afflicted by this deadly disease. Proteins represent some of the most powerful molecular biomarkers to human disease such as cancer. Therefore this proposal will implement state-of-the-art methods in biological mass spectrometry to identify protein biomarkers specific to non-significant and significant CaP. These new protein biomarkers may spur the development of molecular tests that robustly predict the metastatic potential of non-significant CaP. These tests would reduce the physical and mental burdens associated with the overtreatment of patients afflicted by localized CaP. Also, protein biomarkers specific to significant CaP may represent new and effective drug targets to cure patients already afflicted by this deadly disease. We anticipate this proposal will identify the critical molecular targets with the greatest potential to improve the treatment and potentially cure CaP in men.					
15. SUBJECT TERMS None provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	8	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	6
Reportable Outcomes.....	7
Conclusion.....	7
References.....	7
Appendices.....	8

INTRODUCTION


Narrative that briefly (one paragraph) describes the subject, purpose and scope of the research.

My laboratory is currently constructing protein expression libraries of matched normal and cancerous human prostate tissues using quantitative mass spectrometry. Our research progress over the past 12 months has entailed the processing of archived frozen tissues of normal, T2, and T3 staged prostate tissues for proteomic analyses using label-free, quantitative mass spectrometry. We have acquired tissue blocks of whole prostate radical prostatectomies and have focused on optimizing protocols to extract and profile proteins in matched normal and diseased tissue samples using directed mass spectrometry methods. The ultimate outcome of these efforts will be the identification of pathologically-staged protein biomarkers to organ-confined and metastatic human prostate cancers.

BODY

This section of the report shall describe the research accomplishments associated with each task outlined in the approved Statement of Work. Data presentation shall be comprehensive in providing a complete record of the research findings for the period of the report. Provide data explaining the relationship of the most recent findings with that of previously reported findings. Appended publications and/or presentations may be substituted for detailed descriptions of methodology but must be referenced in the body of the report. If applicable, for each task outlined in the Statement of Work, reference appended publications and/or presentations for details of result findings and tables and/or figures. The report shall include negative as well as positive findings. Include problems in accomplishing any of the tasks. Statistical tests of significance shall be applied to all data whenever possible. Figures and graphs referenced in the text may be embedded in the text or appended. Figures and graphs can also be referenced in the text and appended to a publication. Recommended changes or future work to better address the research topic may also be included, although changes to the original Statement of Work must be approved by the Army Contracting Officer Representative. This approval must be obtained prior to initiating any change to the original Statement of Work.

Task: Specific aim1: Construction of mass spectrometry-based protein expression libraries of normal prostate tissue, non-significant CaP tissue, and significant CaP tissue.



Over the past year my laboratory has acquired 5 frozen radical prostatectomy (RP) samples containing T2 stage prostate cancer and normal adjacent tissue to build protein expression signatures of non-significant (organ-confined) and significant (metastatic) human prostate cancer using label-free, quantitative mass spectrometry. Last year we were able to extract up to 100 micrograms of total protein using whole-mount FFPE RP tissue block samples. This was a significant improvement in the amount

of extractable protein that was isolated in needle-biopsied tissue cores in the first year of this research application (e.g. 1-5 ug of total protein). We have been able to increase the amount of extracted protein up to 1 mg of N-linked glycoproteins using frozen whole-mount tissue blocks (Fig. 1). This has greatly enhanced our ability to interrogate the protein expression patterns in non-significant and significant human prostate cancers by nanospray liquid-chromatography tandem mass




Figure 2. Silver-stained SDS-PAGE gel of total protein extracted from sample R90197381.

Detergent solubilized proteins were run into lanes 6-13. A protein standard composed of LNCaP whole cell lysates at .5ug, 1ug, 2ug, and 4ug was loaded into lanes 2-5. Protein isolated from normal adjacent tissues, samples 1 and 2, were loaded into lanes 6-9 (sample 1, lanes 6-7; sample 2, lanes 8-9). Protein isolated from tumor tissues, samples 1 and 2, were loaded into lanes 10-13 (sample 1, lanes 10-11; sample 2, lanes 12-13). 1 (lanes 6, 8, 10, and 12) and 2 (lanes 7, 9, 11, and 13) microliters of sample were subjected to SDS-PAGE.

spectrometry (nano-LC-MS/MS). The frozen tissue blocks provide up to 500X more material to identify human prostate cancer protein biomarkers.

My laboratory has also optimized a new protein-extraction protocol to interrogate glycoproteins in frozen tissue samples using lectin-affinity chromatography methods. This

glycoprotein enrichment




Figure 3. Silver stain of affinity-purified glycoproteins from tumor and normal adjacent prostate tissue (sample D90197381).

protocol facilitates the extraction of N-linked glycoproteins in tissue and facilitates the proteomic interrogation of low-abundance biomarkers in tissue samples. Briefly, tissue samples were extracted with detergent and processed by SDS-PAGE to determine the quantity and quality of tissue extracted proteins (Fig. 2). The detergent-solubilized proteins were subsequently incubated with wheat-germ agglutinin (WGA) and concanavalin-A (ConA) beads, washed, and eluted with soluble N-acetyl glucosamine. The eluted glycoproteins were dialyzed to remove residual detergent, and both the integrity and quantity of glycosylated protein samples was determined by SDS-PAGE and silver-stain analysis (Fig. 3). Equal amounts of tumor and normal adjacent sample were digested with trypsin and subjected to strong cation exchange chromatography (Fig. 4). The individual peptide fractions were collected, desalted, and subjected to nano-LC-MS/MS. This protocol facilitates the mass spectrometry analysis of glycoproteins in cancerous lesions of the prostate and adjacent normal tissue. We have preliminary MS data showing the differentially expression of glycoproteins

such as prostate-specific antigen (PSA) and prostatic specific phosphatase (PSAP), which are well-known androgen-regulated glycoproteins and biomarkers used in the detection of localized prostate cancers (1).

To expedite the discovery of pathologically-staged protein

- We have developed a glycoprotein tissue-extraction protocol has been developed for the proteomic analysis of archived frozen tissue samples.
- We have successfully implemented a directed proteomic approach that has significantly improved our ability to identify and quantify protein expression changes across normal prostate tissue, non-significant prostate cancer, and significant human prostate cancer.

REPORTABLE OUTCOMES: Provide a list of reportable outcomes that have resulted from this research to include:

My laboratory is actively profiling tissue samples at the moment. However, our preliminary analyses have identified glycoprotein expression differences between cancerous and adjacent normal tissue. These differentially expressed glycoproteins encode regulatory enzymes (e.g. DNA-dependent protein kinase-DNAPKC, entonucleotide triphosphate diphosphohydrolase 5-ENTPD5) that have been implicated in the development and invasiveness of localized prostate cancers (3, 4). We will have completed all reported outcomes over the next reporting period.

CONCLUSION: Summarize the results to include the importance and/or implications of the completed research and when necessary, recommend changes on future work to better address the problem. A "so what section" which evaluates the knowledge as a scientific or medical product shall also be included in the conclusion of the report.

The proposed research studies are ongoing. We have not reached any conclusions regarding the completed research to date. We anticipate over the next reporting period that distinct protein expression patterns will be obtained on normal prostate tissue, non-significant prostate cancer, and significant human prostate cancer. These findings will identify novel protein biomarkers to non-significant and significant human prostate cancer.

REFERENCES: List all references pertinent to the report using a standard journal format (i.e. format used in *Science*, *Military Medicine*, etc.).

1. Tosoian J, Loeb S 2010 PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. *ScientificWorldJournal* 10:1919-1931
2. Schmidt A, Claassen M, Aebersold R 2009 Directed mass spectrometry: towards hypothesis-driven proteomics. *Curr Opin Chem Biol* 13:510-517
3. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM 2011 Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. *Cancer Cell* 19:664-678
4. Fang M, Shen Z, Huang S, Zhao L, Chen S, Mak TW, Wang X 2010 The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. *Cell* 143:711-724

APPENDICES: Attach all appendices that contain information that supplements, clarifies or supports the text. Examples include original copies of journal articles, reprints of manuscripts and abstracts, a curriculum vitae, patent applications, study questionnaires, and surveys, etc.

None reported to date.

SUPPORTING DATA: All figures and/or tables shall include legends and be clearly marked with figure/table numbers.

Data analyses are not complete. Completed datasets will be provided over the next reporting period.